<![CDATA[Interpreting Real-World Data and Cross-Trial Comparisons in CLL Studies]]>

<![CDATA[AI Test Predicts Breast Cancer Recurrence Using Standard Pathology Slides]]>

<![CDATA[From Observation to Treatment: The Role of Caregivers and Overcoming VMAT2 Inhibitor Complexities]]>

<![CDATA[Pharmacist-Led Workflows Support Safe Outpatient BiTE Therapy in Multiple Myeloma]]>

<![CDATA[BCMA Biology, Mechanisms of Action, and Unmet Needs in Relapsed/Refractory Multiple Myeloma]]>

<![CDATA[Rationale and Timing: The Evolving Role of BCMA-Targeted Therapies in Relapsed/Refractory Multiple Myeloma ]]>

Real-world data point to patient experience as next battleground for anti-CD20 therapies in RMS, says GlobalData

As real-world evidence (RWE) increasingly shapes competition in the relapsing multiple sclerosis (RMS) market, TG Therapeutics is leaning on